From: Health technology assessment of biosimilars worldwide: a scoping review
HTA reports | Immunogenicity was considered | Risk of switching/interchangeability was considered | Extrapolation of one or more condition was considered | Educational approach about biosimilars was considered | Statement in favour, against or not declared about the adoption/reimbursement of biosimilar | ||
---|---|---|---|---|---|---|---|
Statement in favour | Statement against | Not declared | |||||
Full HTA (n = 2) | 1 | 1 | 1 | 1 | 2 | 0 | 0 |
Mini-HTA (n = 4) | 4 | 4 | 4 | 4 | 4 | 0 | 0 |
Rapid review (n = 64) | 39 | 13 | 42 | 14 | 51 | 0 | 13 |